FDA policy, shifting R&D priorities, and heightened oversight of overseas trials are shaping the future of drug development. Don’t miss the latest in BioPharma!
PDUFA Reauthorization Offers Chance for Clinical Trial Reforms. Will the US Take It?
Source: PharmaVoice
The upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA) could create an opening for Congress to streamline U.S. clinical trials as competition from China’s research sector intensifies. While the FDA-industry fee agreement proposes a fee reduction for applications backed by U.S.-anchored Phase 1 trials, broader reforms would require congressional action. The effort also hinges on whether the FDA can rebuild and retain enough staff to meet its drug-review commitments.
Cancer Still Dominates Pharma R&D. Obesity is Gaining Ground.
Source: PharmaVoice
Cancer remains the largest focus of pharmaceutical R&D, though its pipeline declined for a second consecutive year. At the same time, anti-obesity drug development surged 30.7% this year, and rare disease therapies now account for one-third of all pipeline drugs, underscoring a broader diversification of industry research.
FDA Raises Bar for Foreign Site Inspections as China Trials Surge
Source: BioSpace
The FDA plans to strengthen oversight of foreign clinical trial sites as China’s research activity continues to grow. The agency will expand inspections, work with sponsors earlier to assess data provenance and access, strengthen internal reviewer training, and scrutinize studies where data integrity or participant protections cannot be verified.
